Evaluation of the HYPERSCINT scintillation dosimetry platform for small-field characterization of a Leksell Gamma Knife

The performance of the HYPERSCINT RP-200 with the 0.5mm x 0.5mm detector was evaluated for the characterization of small radiation fields administered using a Leksell Gamma Knife Perfexion radiosurgery device. Overall, our results show that the detector response was in close agreement with Gamma Knife Monte Carlo reference data and film measurements. Based on the obtained results, the plastic scintillation detector shows the potential for rapid validation of output factors and validation of film measurements as well its use in challenging small-field situations encountered with the Gamma Knife.

ISRS 2024 – New York
Mathieu GUILLOT (1), Patrick DELAGE (1), Vincent HUBERT-TREMBLAY (1), Francois THERRIAULT-PROULX (2), Danahé LEBLANC (2) | CHUS – Canada, Medscint – Canada

Development of End-to-End Preclinical Treatment Verification Procedures, Traceable to NPL Air Kerma Primary Standard

Dosimetry audits are an important tool to improve quality of reported results and to support standardization of preclinical radiation research. This work presents how the combination of passive and active detectors, such as the real-time HYPERSCINT scintillation dosimetry solution, with anatomically correct mouse phantoms are adequate for the development of End-to-End dosimetry audits for the independent verification of preclinical radiation treatments.

The traceability of the detectors’ calibration to primary standards strengthens the dosimetry chain in the validation of preclinical plans, and it is consistent with the current practice for dose traceability of clinical radiotherapy treatments. Their implementation at national and regional levels could lead to databases of anonymised records, which will positively impact the dissemination of best practices and sharing of validated results.

6th Conference on small animal precision image-guided radiotherapy
Ileana Silvestre Patallo (1), Rebecca Carter (2)(3), Andrew Nisbet (2), Anna Subiel (1), Giuseppe Schettino (1) | 1. National Physical Laboratory, UK, 2. University College London, UK, 3. Cancer Institut, UK

Performance characterization of a novel hybrid dosimetry insert for simultaneous spatial, temporal, and motion-included dosimetry for MR-linac

The increased treatment complexity and the motion-delivery interplay during stereotactic body radiotherapy (SBRT) on an MR-linac treatments require MR-compatible motion phantoms with time-resolved dosimeters to validate end-to-end workflows. This study demonstrates the excellent suitability of a the Medscint novel hybrid film-scintillators cassette for simultaneous multi-spatial, temporal, and motion-included dosimetry.

MEDICAL PHYSICS
Prescilla Uijtewaal (1), Pim Borman (1), Benjamin Côté (2), Yoan LeChasseur (2), François Therriault-Proulx (2), Rocco Flores (3), Stephanie Smith (3), Grant Koenig (3), Bas Raaymakers (1), Martin Fast (1) | 1. Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands, 2. Medscint, Québec, Quebec, Canada, 3. Modus QA, London, Ontario, Canada

Patient Specific QA for External Beam Radiotherapy Using the HYPERSCINT Plastic Scintillation Detector

Plastic scintillation detectors have interesting dosimetric properties, including small size and energy independence. These advantages make them well suited for VMAT patient-specific QA, either alone or in conjunction with a detector matrix. This work aims to determine if the HYPERSCINT scintillation dosimetry research platform can replace the classic ion chamber in a clinical patient-specific QA workflow.

2020 AAPM AM
M.Goulet | CISSS – Chaudiere-Appalaches, Lévis, QC, CA

Small field dosimetry of a Varian TrueBeam High Definition MLC linear accelerator using theHyperscint RP200 scintillation detector.

To evaluate the performance of the new Hyperscint RP200 plastic scintillator for small field measurements of a Varian TrueBeam linear accelerator in comparison with the current state-of-the-art methodology in the clinic.

2021 COMP ASM
L.Gingras, B.Côté, F.Berthiaume, S.Lambert-Girard, D.Leblanc, L.Archambault, L.Beaulieu, F.Therriault-Proulx | CHU de Quebec – Universite Laval, QC, CA, Département de radio-oncologie et Axe Oncologie du CRCHU de Québec, QC, CA, MedScint, QC, CA